Grey Wolf Animal Health Corp (WOLF) Fair Value & Analysis
Consumer Cyclical · CA · Market cap C$61.1M
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from C$1.35 to C$1.06 (−21.5%) since Jun 23, 2026. Share price +3.6% over the past month.
Price vs Fair Value (12 months)
12‑month range C$0.9922 – C$1.83 · fair‑value band C$0.7200 – C$1.32 · the C$1.79 price screens above the C$1.06 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Grey Wolf Animal Health Corp (WOLF) currently trades at C$1.79, while our model-based Fair Value estimate is C$1.06 — implying the stock looks roughly 40.8% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Grey Wolf Animal Health Corp generated revenue of C$36.6M at a net margin of 4.9%. Revenue grew 10.5% year over year. It earns a return on equity of 5.6%. Net debt stands at C$17.4M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Grey Wolf Animal Health Corp. operates as an animal health and wellness company in Canada. The company operates in two segments, Animal Health Business Unit and Pharmacy Business Unit. It engages in the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics, as well as offers pharmaceuticals for the human and animal health markets. The company provides dexmedetomidine hydrochloride oromucosal gel under the SILEO name; sedative analgesic and reversing agents for companion animals under the SEDAJECT and ATAJECT names; prescription drugs under the THYRO-TABS CANINE name; and wound care products, including medical grade tubes, viscose net dressings, alginate dressing, absorbent foam dressing, superabsorbent dressing, and silicone perforated tapes, as well as medical pet shirt protective wear products, such as pet shirt, pets boot, head cover, and leg sleeves. It also offers disposables comprising syringes, needles, and IV cathet…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Grey Wolf Animal Health Corp reported revenue of C$35.8M in FY2025 versus C$13.1M in FY2021, a compound +28.6%/yr. Reported net income was C$1.7M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Personal Services stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Rollins, Inc ROL | $44.41 | $21.11 | -52% |
| Service Corporation SCI | $73.84 | $33.66 | -54% |
| H&R Block, Inc HRB | $37.21 | $78.83 | +112% |
| Frontdoor, Inc FTDR | $67.10 | $75.55 | +13% |
| Bright Horizons Family Solutions Inc BFAM | $64.02 | $72.82 | +14% |
| Fu Shou Yuan International Group FSHUF | $0.3800 | $0.5700 | +50% |
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Frequently asked questions
Is Grey Wolf Animal Health Corp (WOLF) undervalued?
What is the fair value of WOLF?
What is the quality score of WOLF?
What is the revenue of Grey Wolf Animal Health Corp (WOLF)?
What is the net profit margin of WOLF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.